Advocating for a world where intellectual
property law serves the public interest.
The Intergovernmental Committee on Traditional Knowledge, Traditional Cultural Expressions, and Genetic Resources (IGC) meets this week at WIPO. The Committee is working on negotiating a new treaty or soft law instrument on Traditional Knowledge, Traditional Cultural Expressions, and Genetic Resources. This week’s work will focus on genetic resources, with future meetings this year on traditional […]
Since the publication of my post (PAIPO is dead. Long live PAIPO) last week, I have received the full text of the Ministerial Decisions passed at Brazzaville in November 2012 (AUMINST Dec. (V) (01)) from the AU. The relevant paragraph (2.2.15) reads: AMCOST takes note of the draft statutes of the Pan-African Intellectual Property Organisation […]
Excerpt from a Fact Sheet from Public Citizen’s Global Trade Watch. Click here for the full Fact Sheet Eli Lilly and Company has initiated formal proceedings under the North American Free Trade Agreement (NAFTA) to attack Canada’s standards for granting drug patents, claiming that the denial of a medicine patent is an expropriation of its […]
[Reposted with permission from B.I.T.S. in Bits] Access to climate data is important. Last 3 December 2012, ALERTNET reported[1] that in Colombia, climate researchers complain of lack of access to data because it is expensive. Its main climate data service, the Institute of Hydrology, Meteorology and Environmental Studies, charges more for access to its information […]
Europolitics reports that European Trade Commissioner Karel De Gucht will travel to Canada next week “in the hope of concluding trade talks with the two countries before the EU’s 27 heads of state and government meet in Brussels.” However, Canadian Trade Minister Ed Fast recently told the Globe and Mail that he was more conerned […]
New Paper Shows Follow On Patents Are Common, and Commonly Extend the Patent Life of Pharmaceuticals
[by Amy Kapczynski] Chan Park, Bhaven Sampat and I recently published in PLoS, perhaps of interest to folks here. We provide data about the ubiquity and significance of so-called “secondary” patents in pharma (e.g. salt patents, polymorph patents, dosage and method of treatment patents, etc). The full paper is here: Polymorphs and Prodrugs and Salts […]
Posts by Category
- Video
- User Rights Network
- US Domestic Policies
- US Domestic Legislation
- Transparency
- Trade Agreements
- Takedown
- Trade Disputes
- Trademark
- Round-up
- Regional Fora
- Surveys and Data
- Positive Agenda
- Patent Pledges
- Open
- News
- Multilateral Fora
- Limitations and Exceptions
- IP & Research
- IP and Human Rights
- Industry Initiatives
- Flagged
- Fair Use
- Events
- Empirical Research
- Document Library
- Coronavirus
- Brazil
- Blog
- Bilateral Trade Pressures
- Artificial Intelligence
- AI
- Africa Group Work Plan Proposal
- Africa: Copyright & Public Interest
- Access to Medicine
- Academic Resources